276. Detection of Rhizopus oryzae-Specific Antigen (RSA) in Serum and Bronchial Alveolar Lavage Is a Potential Early Diagnostic Marker in Mucormycosis by R. oryzae
Wataru Shibata, MD, PhD; Koichi Yamada, MD, PhD; Mamiyo Niki, PhD; Satoshi Yamagoe, PhD; Yoshitsugu Miyazaki, MD, PhD; Yukihiro Kaneko, MD, PhD; Hiroshi Kakeya, MD, PhD; Osaka City University, Osaka, Japan; National Institute of Infectious Diseases, Tokyo, Japan
Session: 40. Fungal Diagnostics
Thursday, October 3, 2019: 12:15 PM

Background. The diagnosis of mucormycosis was made by the identification of an organism in the histopathology with culture confirmation. However, culture often yields no growth, and histopathological identification of organism with typical of mucorales is sometimes difficult. Therefore, a reliable new diagnostic tool is expected. We reported a novel Rhizopus-specific antigen (23kDa, named protein RSA) by screening with a signal sequence trap was detected at significantly higher concentrations in serum and in lung homogenates in the infected mice on day 4. And the result of our earlier study was a possible diagnostic marker of mucormycosis (Sato K, et al. Medical Mycology, 2017, 55,713–719). Here, we examined whether the RSA was detected on early stage in sera and bronchial alveolar lavage (BAL) of infected mice.

Methods. We developed the ELISA Kit using monoclonal antibody for RSA. The mice were injected with cortisone acetate and cyclophosphamide, and RSA concentrations in serum and in lung homogenates in the infected mice on day 1, 2, 3, and 4. Then the concentration of RSA in sera and BAL was evaluated using the ELISA Kit for RSA.

Results. The RSA was detected in sera and BAL on day 1, 2, 3, and 4. The concentration of RSA in sera and BAL were significantly higher on day 1 as compared with uninfected mice. And the concentration of RSA in sera was the upward trend through day 1 to 4. However, the concentration of RSA in BAL was stable through day 1 to 4.

Conclusion. The RSA is a potential early diagnostic marker in mucormycosis by R. oryzae.

Disclosures. All authors: No reported disclosures.

277. Identification and Antifungal Susceptibility of Candida Species Isolated from Bloodstream Infections Over a 14-Year Period
Ahmadi, MD, MD PhD; Clark Andrew, PhD; Michael S. Lianakos, MD, ScD 2; Adrian Zelazny, PhD, ABMM;
1 NIH, Bethesda, Maryland; 2 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
Session: 40. Fungal Diagnostics
Thursday, October 3, 2019: 12:15 PM

Background. Invasive infections caused by Candida species are associated with significant morbidity and mortality. Historically, C. albicans has been the predominant species recovered from patients with candidemia. However, the changing epidemiology of invasive candidiasis now includes more non-C. albicans species, which may exhibit intrinsic resistance or reduced susceptibility to antifungal agents used for therapeutic intervention. We sought to evaluate the epidemiology and susceptibility of invasive Candida spp. isolates causing bloodstream infections at the NIH Clinical Center over a 14-year period.

Methods. Candida spp. isolates causing bloodstream infections between 2004 and 2018 were identified. Retrospective chart review was performed for infected patients in accordance with the IRB. All Candida isolates were recovered from frozen storage previously obtained from the Department of Microbiology, NIH, Bethesda, Maryland.

Results. Between 2004-2018, we identified 98 unique clinical isolates from 77 patients with candidemia. Records from 75 of these patients were able to be reviewed, and the 30-year and 90-day mortalities were 24% and 52%, respectively. The average age of patients with candidemia was 41.3 years (range 6.5 to 76.9 years). Thirty-one of 75 (41%) were female and 44 were male. At the time of culture positivity was 41.3 years (range 6.5 to 76.9 years). An average age of 48.7 years (range 6.5 to 32.4 years). Thirty-one of 75 (41%) were female and 44 were male. C. albicans was the third-most prevalent (28%, N = 22) and C. glabrata (33%, N = 23), followed by C. tropicalis (8%, N = 8) and C. krusei (6%, N = 6). As expected, fluconazole resistance was prevalent among C. glabrata (70%, N = 16) and C. krusei (100%, N = 6); however, a sizable proportion of C. parapsilosis (11%, N = 3), C. tropicalis (63%, N = 5) and C. albicans (22%, N = 4) strains also exhibited fluconazole resistance.

Conclusion. Our findings illustrate a high prevalence of non-C. albicans Candida spp. as the causative agents of bloodstream infections among patients at our institution. The clinical risk factors associated with the development of candidemia and azole resistance, as well as the molecular mechanisms of antifungal resistance are under investigation.

Disclosures. All authors: No reported disclosures.

278. CNS Blastomycosis: A Descriptive Analysis and Review of Diagnosis and Treatment
Kathryn Majdick, MD; Keaton Kaye, BS2; Mahmoud Shorman, MD, MD; University of Tennessee, Knoxville, Tennessee; University of Tennessee, Knoxville, Tennessee
Session: 40. Fungal Diagnostics
Thursday, October 3, 2019: 12:15 PM

Background. Blastomycosis is a systemic infection, well known to regions of the Southeastern and Ohio River Basin in the United States. Inhalation of the dimorphic fungus most often causes pulmonary manifestations. Hematogenous dissemination can affect various organs in immunocompromised hosts. Central Nervous System (CNS) involvement is a rare manifestation of Blastomycosis infection, accounting for 5%–10% of extra pulmonary involvement. It is important to diagnosis early and treat due to the increased morbidity in high-risk patients.

Methods. Our study retrospectively reviewed cases from a Tertiary Care Facility in East Tennessee from 2011 to 2018 with the diagnosis of CNS Blastomycosis. Data collection included demographics, risk factors, varied clinical presentation, methods of diagnosis, treatment plans and outcomes.

Results. Total of 8 CNS Blastomycosis cases were identified. Detailed demographics are presented in Table 1. The average age was 52 years, 7 (87.5%) were male. Of the 8 cases were tested for HIV, all of which were negative. MRI brain imaging was utilized in 7 (87.5%) cases, which demonstrated lesion enhancements, Table 2 and Images 1 and 2. CSF was collected in 6 (75%) patients. 5 patients (62%) presented with neurological complaints. All patients received Liposomal Amphotericin B (LAmpB), followed by a prolonged course of azoles. 5 (62%) developed acute renal insufficiency after starting Amphotericin B. 2 (25%) died.

Conclusion. CNS Blastomycosis is a rare diagnosis with increased morbidity and mortality. Obtaining brain imaging in addition to lumbar puncture can help in timely diagnosis of CNS Blastomycosis. Treatment involves lipid formulation of Amphotericin B followed by oral azole therapy, preferably voriconazole. Renal insufficiency was a common finding after this treatment. A high level of suspicion is crucial for recognition of CNS Blastomycosis in endemic regions of the SouthEastern and Ohio River Basin.

| Table 1. Characteristics of 8 Patients with CNS Blastomycosis |
|---------------------------------------------------------------|
| **Characteristics**                                           | **Pt with CNS Blastomycosis (n=8)** |
| **Age, Median years (range)**                                | 52 (41-61)                           |
| **Sex**                                                      |                                        |
| Male                                                         | 7 (87.5)                             |
| Female                                                       | 1 (12.5)                             |
| **Immune-compromised State**                                 |                                        |
| **Liver Transplant**                                         | 2 (25)                               |
| **Diabetes Mellitus Type II**                                | 1 (12.5)                             |
| **Solid Organ Transplant**                                  | 1 (12.5)                             |
| **HIV/AIDS**                                                 | 6 (75%)                              |
| **Tobacco abuse**                                            | 5 (62.5)                             |
| **Alcohol abuse**                                            | 1 (12.5)                             |
| **Hepatitis C**                                              | 1 (12.5)                             |
| **Autoimmune Disease**                                       | 1 (12.5)                             |

1. patient had >1 of the conditions
2. Liver Transplant
3. Autoimmune Disease included antiparitiat +, RF +

Disclosures. All authors: No reported disclosures.